Results 31 to 40 of about 9,615 (165)
The first-in-class Bruton’s tyrosine kinase inhibitor ibrutinib has proven clinical benefit in B-cell malignancies; however, atrial fibrillation (AF) has been reported in 6–16% of ibrutinib patients.
Jennifer R. Brown +26 more
doaj +1 more source
Ibrutinib is a drug that inhibits the protein Burton’s tyrosine kinase and thereby the nuclear translocation of Nrf2, which played a key role in mediating the activation of antioxidants during stress conditions and ferroptosis resistance.
Jin-Feng Zhu +8 more
doaj +1 more source
Ibrutinib is a targeted therapy drug that blocks the activity of Bruton’s tyrosine kinase, and it is an approved treatment for several mature B-cell malignancies including chronic lymphocytic leukaemia (CLL).
Sara Kristina Viberg Tjønnfjord +3 more
doaj +1 more source
Background In preclinical studies of pancreatic ductal adenocarcinoma (PDAC), ibrutinib improved the antitumor efficacy of the standard of care chemotherapy.
Li Zhang +28 more
doaj +1 more source
Extrahepatic metabolism of ibrutinib [PDF]
Ibrutinib is a first-in-class Bruton's kinase inhibitor used in the treatment of multiple lymphomas. In addition to CYP3A4-mediated metabolism, glutathione conjugation can be observed.
Rood, Johannes J M +15 more
core
ROR1 – a receptor tyrosine kinase – is overexpressed in CLL. Ibrutinib, a Bruton's tyrosine kinase inhibitor, is clinically effective in CLL but patients may develop resistance. We evaluated the effect of an ROR1 inhibitor, KAN0441571C, in CLL cells from
Amineh Ghaderi +9 more
doaj +1 more source
Results from a phase 1b/2 study of ibrutinib combination therapy in advanced urothelial carcinoma [PDF]
Ibrutinib is a first-in-class Bruton’s tyrosine kinase inhibitor approved for the treatment of various B-cell malignancies and chronic graft-versus-host disease.
Jones, Robert J +43 more
core +1 more source
: The BTK inhibitor ibrutinib has demonstrated a remarkable therapeutic effect in mantle cell lymphoma (MCL). However, approximately one-third of patients do not respond to the drug initially.
Jimmy Lee +14 more
doaj +1 more source
Dual Mechanism of Severe Bleeding Diathesis in a Patient with CLL: Acquired Von Willebrand Syndrome and Ibrutinib - Mediated Platelets Dysfunction [PDF]
We here report an informative case of severe bleeding diathesis in a patient with Chronic Lymphocytic Leukaemia (CLL), due to Acquired Von Willebrand Syndrome (AVWS) and impaired platelets aggregation under the treatment with Ibrutinib. Keywords:
Novak, U, Bürki, S
core +1 more source
: Ibrutinib is a novel oral therapy that has shown significant efficacy as initial treatment of chronic lymphocytic leukemia (CLL). It is a high-cost continuous therapy differing from other regimens that are given for much shorter courses.
James I. Barnes +6 more
doaj +1 more source

